Clinical trial
EW-A-401 to Treat Intermittent Claudication
NCT00080392 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00080392 |
|---|---|
| Title | EW-A-401 to Treat Intermittent Claudication |
| Official title | Modulation of Vascular Endothelial Growth Factor (VEGF) Using an Engineered Zinc-Finger Transcription Factor to Treat Lower Limb Intermittent Claudication |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Intermittent Claudication, Arteriosclerosis |
| Intervention type | Drug |
| Interventions | DNA Plasmid Vector, EW-A-401 DNA Plasmid Vector |
| Enrollment | 10 |
| Start date | Mar 27, 2004 |
| Completion | Dec 29, 2011 |
| First posted | Mar 30, 2004 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: